Clomipramine Hydrochloride
FDA-approved product (capsule, oral), marketed as Anafranil, Clomipramine Hydrochloride.
- Registered studies
- 33
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Depressive disorder
- Major depressive disorder
- Obsessive-compulsive disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Non-selective monoamine reuptake inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli37.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
33registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Clomipramine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- LypressinExisting use: Vasopressin and analogues59.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BrexpiprazoleExisting use: Major depressive disorder, Psychosis, Schizoaffective disorder and 1 more59.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Baloxavir MarboxilExisting use: Influenza, Viral disease59.2% AI-predicted activityagainst M. tuberculosis24 registered studies
- Fluvastatin SodiumExisting use: Cardiovascular disease, Familial hypercholesterolemia, Hypercholesterolemia59.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- OndansetronExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 4 more59.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethyldopaExisting use: Hypertension59.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Asciminib HydrochlorideExisting use: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic myelogenous leukemia, Neoplasm59.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- DofetilideExisting use: Atrial fibrillation, Atrial flutter, Cardiac arrhythmia and 1 more59.0% AI-predicted activityagainst M. tuberculosis22 registered studies
- Fedratinib HydrochlorideExisting use: Myelofibrosis, Myeloproliferative disorder, Neoplasm and 1 more59.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- MetolazoneExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more59.0% AI-predicted activityagainst M. tuberculosis36 registered studies
- Nelfinavir MesylateExisting use: HIV infection, HIV-1 infection59.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Raltegravir PotassiumExisting use: HIV infection, HIV-1 infection, Immunodeficiency disease59.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Citalopram vs Clomipramine vs Placebo in Recurrent Depression
NCT01575158 · start 1997-10
Registered record
- Registry ID
- NCT01575158
- Conditions
- Depression
- Interventions
- Citalopram; Clomipramine; placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 1997-10
- Completion
- 2007-09
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDepressionInterventionCitalopram; Clomipramine; placeboPhaseNot applicableRegistry statusCompletedTo Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
NCT00913952 · start 1994-04
Registered record
- Registry ID
- NCT00913952
- Conditions
- Depression
- Interventions
- Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions; Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions; Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1994-04
- Completion
- 1994-06
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDepressionInterventionGeneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions; Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions; Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed ConditionsPhasePhase 1Registry statusCompletedTo Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions
NCT00913783 · start 1992-11
Registered record
- Registry ID
- NCT00913783
- Conditions
- Depression
- Interventions
- Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals); Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1992-11
- Completion
- 1992-12
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDepressionInterventionClomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals); Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)PhasePhase 1Registry statusCompleted